AryoGen Bevacizumab Biosimilar Compares To Avastin
Iranian Player Has Ambitions In Biotech Space
Iranian player AryoGen has received a boost after a recent study revealed that the firm’s bevacizumab biosimilar was non-inferior to reference product Avastin terms of efficacy and tolerability.
You may also be interested in...
Pfizer has received a pan-European marketing authorization for its Zirabev biosimilar bevacizumab, a rival to Genentech’s Avastin. The nod marks Pfizer’s second European approval for an oncology biosimilar.
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.